Physician profile
Leticia Castillo Kontak
NPI 1891994968
$7,802.90
in general payments reported to CMS, 2019-2025
9 companies · $4,643 in 2025
The $4,643 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $102 · 2022: $39.83 · 2023: $2,097 · 2024: $771 · 2025: $4,643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,394 · Food and Beverage: $3,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,393.79 |
| Food and Beverage | $3,116.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $6,876.90 | 2019-2025 | Pascal, Evoque, Sapien 3 Ultra Resilia |
| Abbott Laboratories | $711.90 | 2022-2025 | Amplatzer Amulet, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.87 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $44.57 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.16 | 2024 | |
| Boston Scientific Corporation | $17.56 | 2025 | Farapulse |
| Janssen Pharmaceuticals, INC | $16.71 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2019 | |
| Amgen INC. | $13.12 | 2023 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leticia Castillo Kontak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.